First Trust Advisors LP Has $35.71 Million Holdings in Elanco Animal Health Incorporated $ELAN

First Trust Advisors LP increased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 37.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 2,500,822 shares of the company’s stock after acquiring an additional 675,497 shares during the quarter. First Trust Advisors LP’s holdings in Elanco Animal Health were worth $35,712,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ELAN. Nuveen LLC acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at approximately $115,212,000. Dimensional Fund Advisors LP increased its stake in Elanco Animal Health by 14.3% in the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after acquiring an additional 2,563,740 shares during the last quarter. Jennison Associates LLC raised its position in Elanco Animal Health by 322.0% during the second quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock valued at $46,192,000 after purchasing an additional 2,468,122 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. Finally, Primecap Management Co. CA boosted its holdings in shares of Elanco Animal Health by 3.1% in the 2nd quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after purchasing an additional 1,543,279 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ELAN shares. UBS Group boosted their price target on Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Barclays assumed coverage on Elanco Animal Health in a research note on Tuesday. They set an “overweight” rating and a $30.00 target price for the company. Stifel Nicolaus raised their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Wednesday, November 19th. Finally, JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $22.78.

Elanco Animal Health Trading Down 5.7%

ELAN opened at $20.45 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $23.70. The company’s 50 day moving average price is $21.69 and its two-hundred day moving average price is $17.93. The firm has a market capitalization of $10.16 billion, a price-to-earnings ratio of 340.96, a PEG ratio of 2.94 and a beta of 1.86.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the previous year, the business earned $0.13 earnings per share. Elanco Animal Health’s revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.